
Oral drug blocks coronavirus transmission in ferrets within 24 hours: Study
Treating novel coronavirus infection in ferrets with the antiviral drug Molnupiravir completely suppressed virus transmission among the mammals within 24 hours, reports a new study which may lead to a new therapeutic to curb the Covid-19 pandemic.
The researchers, including those from the Georgia State University in the US, originally discovered that the drug -- also known as MK-4482/EIDD-2801 -- is potent against influenza viruses.
In the study, published in the journal Nature Microbiology, the scientists repurposed MK-4482/EIDD-2801 against the novel coronavirus, and used a ferret model to test the effect of the drug in halting virus spread.
“This is the first demonstration of an orally available drug to rapidly block SARS-CoV-2 transmission. MK-4482/EIDD-2801 could be game-changing,” said Richard Plemper, a co-author of the study from Georgia State University.
Until mass vaccination is available, the scientists believe interrupting widespread community transmission of SARS-CoV-2 is paramount to managing the pandemic.
“We noted early on that MK-4482/EIDD-2801 has broad-spectrum activity against respiratory RNA viruses and that treating infected animals by mouth with the drug lowers the amount of shed viral particles by several orders of magnitude, dramatically reducing transmission,” said Plemper. “These properties made MK-4482/EIDD-2801 a powerful candidate for pharmacologic control of Covid-19,” he added.
The scientists infected ferrets with SARS-CoV-2, and initiated treatment with MK-4482/EIDD-2801 when the animals started to shed virus from the nose.
“When we co-housed those infected and then treated source animals with untreated contact ferrets in the same cage, none of the contacts became infected,” said Josef Wolf another co-author of the study. By comparison, all contacts of source ferrets that had received placebo became infected, the study noted.
If these ferret-based results translate to humans in further studies, the scientists believe Covid-19 patients treated with the drug could become non-infectious within 24 hours after the beginning of treatment.
They noted that the drug is currently in advanced phase II/III clinical trials against SARS-CoV-2 infection to check for its effectiveness in curbing the transmission of the virus.
(This story has been published from a wire agency feed without modifications to the text.)
Follow more stories on Facebook and Twitter

Earth’s ice loss now in worst-case zone
- Altogether, an estimated 28 trillion metric tons of ice have melted away from the world’s sea ice, ice sheets and glaciers since the mid-1990s.

Study says nuclear war might trigger big El Nino and decreased seafood

Study suggests women influenced coevolution of dogs, humans

Scientists find mechanism behind irritable bowel syndrome

Human brain may get beaten by AI in chess, but not in memory: Study

Neurodegenerative diseases can be prevented by deep sleep

Gene editing techniques helpful in retinal degeneration treatment

Dramatic changes to radiotherapy treatments in England due to Covid-19

Indian-origin expert leads UK study on cancer survival chances

German scientists make paralyzed mice walk again

In her element: Talking to theoretical physicist Rohini M Godbole

Study sheds light on role played by immune system's T-cells against coronavirus

Direct current stimulation over brain's Wernicke area can help learning words

New study explains how SARS-CoV-2 may seize human cells
